Investor centre

Syncona is a leading FTSE250 company focused on founding, building and funding global leaders in life science

We aim to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.

Syncona: 30 September 2020

Net assets

£1,366.7m

Fully diluted NAV per share

203.4p

Life science portfolio value

£666.6m

Capital pool supporting investment in life science

£700.1m

Portfolio snapshot

  • 10 portfolio companies in innovative areas of life science
  • 800+ employees across Syncona portfolio
  • 10 live clinical trials across the portfolio